Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEBEN: Lenalidomide + Bendamustine in Relapsed or Primary Refractory Hodgkin Lymphoma
2011-002810-35Phase 2Active
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and bendamustine in Hodgkin lymphoma (HL), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoints: Best tolerated and effective lenalidomide dose (dose-finding) and Safety profile (AE/SAE rate). Started Mar 2012; status: active.
02
Drugs
lenalidomidebendamustine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2011-002810-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002810-35.